Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

KPC PharmaceuticalsInc Temettü

Temettü kriter kontrolleri 4/6

KPC PharmaceuticalsInc kazançlarla iyi bir şekilde karşılanan, 1.26% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

1.3%

Temettü verimi

33%

Ödeme oranı

Sektör ortalama getirisi	1.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	CN¥0.200
Hisse başına kazanç	CN¥0.60
Temettü verim tahmini	0.6%

Son temettü güncellemeleri

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Recent updates

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 600422 şirketinin temettü ödemeleri son 10 yıldır dalgalı seyretti.

Büyüyen Temettü: 600422 şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

KPC PharmaceuticalsInc Piyasaya Karşı Temettü Getirisi

600422 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (600422)	1.3%
Pazarın Alt %25'i (CN)	0.6%
Pazarın En İyi %25'i (CN)	2.2%
Sektör Ortalaması (Pharmaceuticals)	1.7%
Analist tahmini (600422) (3 yıla kadar)	0.6%

Önemli Temettü: 600422 'in temettüsü ( 1.26% ), CN piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 0.58% ) daha yüksektir.

Yüksek Temettü: 600422 'in temettüsü ( 1.26% ), CN piyasasındaki temettü ödeyenlerin en üst %25'ine ( 2.21% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Oldukça düşük ödeme oranı ( 33.3% ) ile 600422 'un temettü ödemeleri kazançlarla oldukça iyi bir şekilde karşılanıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Düşük nakit ödeme oranı ( 20.9% ) sayesinde 600422 'un temettü ödemeleri nakit akışları tarafından iyi bir şekilde karşılanmaktadır.

KPC PharmaceuticalsInc Temettü

Temettü kriter kontrolleri 4/6

Anahtar bilgiler

Son temettü güncellemeleri

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Recent updates

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Price target decreased by 7.1% to CN¥25.01

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Full year 2023 earnings: EPS and revenues miss analyst expectations

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

New 90-day high - CN¥11.67

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin